Keryx Biopharmaceuticals, Inc. (KERX) Given Average Rating of “Hold” by Brokerages

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has earned a consensus recommendation of “Hold” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $7.28.

A number of research analysts recently weighed in on the company. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th.

ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/keryx-biopharmaceuticals-inc-kerx-given-average-rating-of-hold-by-brokerages.html.

Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 1.97% during trading on Thursday, reaching $6.46. The company had a trading volume of 1,221,989 shares. The company’s market capitalization is $767.13 million. The firm’s 50 day moving average is $7.22 and its 200-day moving average is $6.76. Keryx Biopharmaceuticals has a 12 month low of $4.11 and a 12 month high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.51 million. During the same quarter in the previous year, the business posted ($0.42) EPS. Keryx Biopharmaceuticals’s revenue was up 62.4% compared to the same quarter last year. On average, equities analysts expect that Keryx Biopharmaceuticals will post ($1.23) earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Keryx Biopharmaceuticals by 5.1% during the second quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after purchasing an additional 349,521 shares in the last quarter. State Street Corp lifted its stake in shares of Keryx Biopharmaceuticals by 20.1% during the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock worth $21,432,000 after purchasing an additional 582,624 shares in the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of Keryx Biopharmaceuticals by 24.3% during the second quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after purchasing an additional 326,285 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Keryx Biopharmaceuticals by 6.9% during the second quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock worth $7,881,000 after purchasing an additional 70,420 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Keryx Biopharmaceuticals by 3.5% during the second quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock worth $6,963,000 after purchasing an additional 32,687 shares in the last quarter. Institutional investors own 65.19% of the company’s stock.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply